Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Manjunath P Pai

Showing results (31-40 of 184) with videos related to

Pageof 19
Sort By:
Clinical Pharmacokinetics|October 30, 2017
Population Pharmacokinetics and Dosing Considerations for the Use of Linezolid in Overweight and Obese Adult PatientsPiergiorgio Cojutti, Manjunath P Pai, Federico Pea
Antimicrobial Agents and Chemotherapy|January 19, 2017
Peak Measurement for Vancomycin AUC Estimation in Obese Adults Improves Precision and Lowers BiasManjunath P Pai, Joseph Hong, Lynne Krop
Pharmacotherapy|November 19, 2022
Removing race and body surface area indexation for estimated kidney function based drug dosing: Aminoglycosides as justification of these principlesManjunath P Pai, Sirima Sitaruno, Mohamed Abdelnabi
Pharmacotherapy|February 24, 2025
GLP-1RA-induced delays in gastrointestinal motility: Predicted effects on coadministered drug absorption by PBPK analysisLevi Hooper, Shuhan Liu, Manjunath P Pai
Clinical Pharmacokinetics|July 4, 2014
Levofloxacin dosing regimen in severely morbidly obese patients (BMI ≥40 kg/m(2)) should be guided by creatinine clearance estimates based on ideal body weight and optimized by therapeutic drug monitoringManjunath P Pai, Piergiorgio Cojutti, Federico Pea
Clinical Pharmacokinetics|April 9, 2015
Pharmacokinetics and pharmacodynamics of continuous infusion meropenem in overweight, obese, and morbidly obese patients with stable and unstable kidney function: a step toward dose optimization for the treatment of severe gram-negative bacterial infectionsManjunath P Pai, Piergiorgio Cojutti, Federico Pea
Expert Opinion on Drug Metabolism & Toxicology|March 23, 2011
The effects of obesity on drug pharmacokinetics in humansGlynn A Morrish, Manjunath P Pai, Bruce Green
Antimicrobial Agents and Chemotherapy|August 19, 2015
Optimizing the initial amikacin dosage in adultsBryan P White, Ben Lomaestro, Manjunath P Pai
Scientific Reports|April 18, 2025
A comparison between radiomic biological age and chronological age in estimating kidney functionRadin Alikhani, Steven R Horbal, Manjunath P Pai
Antimicrobial Agents and Chemotherapy|December 30, 2009
Clinical pharmacokinetics of oral controlled-release 5-fluorocytosineManjunath P Pai, Hollie Bruce, Linda A Felton
Pageof 19

Showing results (31-40 of 184) with videos related to

Sort By:
Pageof 19
Clinical Pharmacokinetics|October 30, 2017
Population Pharmacokinetics and Dosing Considerations for the Use of Linezolid in Overweight and Obese Adult PatientsPiergiorgio Cojutti, Manjunath P Pai, Federico Pea
Antimicrobial Agents and Chemotherapy|January 19, 2017
Peak Measurement for Vancomycin AUC Estimation in Obese Adults Improves Precision and Lowers BiasManjunath P Pai, Joseph Hong, Lynne Krop
Pharmacotherapy|November 19, 2022
Removing race and body surface area indexation for estimated kidney function based drug dosing: Aminoglycosides as justification of these principlesManjunath P Pai, Sirima Sitaruno, Mohamed Abdelnabi
Pharmacotherapy|February 24, 2025
GLP-1RA-induced delays in gastrointestinal motility: Predicted effects on coadministered drug absorption by PBPK analysisLevi Hooper, Shuhan Liu, Manjunath P Pai
Clinical Pharmacokinetics|July 4, 2014
Levofloxacin dosing regimen in severely morbidly obese patients (BMI ≥40 kg/m(2)) should be guided by creatinine clearance estimates based on ideal body weight and optimized by therapeutic drug monitoringManjunath P Pai, Piergiorgio Cojutti, Federico Pea
Clinical Pharmacokinetics|April 9, 2015
Pharmacokinetics and pharmacodynamics of continuous infusion meropenem in overweight, obese, and morbidly obese patients with stable and unstable kidney function: a step toward dose optimization for the treatment of severe gram-negative bacterial infectionsManjunath P Pai, Piergiorgio Cojutti, Federico Pea
Expert Opinion on Drug Metabolism & Toxicology|March 23, 2011
The effects of obesity on drug pharmacokinetics in humansGlynn A Morrish, Manjunath P Pai, Bruce Green
Antimicrobial Agents and Chemotherapy|August 19, 2015
Optimizing the initial amikacin dosage in adultsBryan P White, Ben Lomaestro, Manjunath P Pai
Scientific Reports|April 18, 2025
A comparison between radiomic biological age and chronological age in estimating kidney functionRadin Alikhani, Steven R Horbal, Manjunath P Pai
Antimicrobial Agents and Chemotherapy|December 30, 2009
Clinical pharmacokinetics of oral controlled-release 5-fluorocytosineManjunath P Pai, Hollie Bruce, Linda A Felton
Pageof 19